Barclays
HZNP

Barclays’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Barclays’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-699,553
Closed -$80.9M – 5461
2023
Q3 		$80.9M Sell
699,553
-279,641
-29% -$30M 0.05% 365
2023
Q2 		$101M Sell
979,194
-568,050
-37% -$59.9M 0.06% 272
2023
Q1 		$169M Buy
1,547,244
+789,395
+104% +$87.3M 0.08% 170
2022
Q4 		$86.2M Sell
757,849
-3,094,447
-80% -$257M 0.04% 318
2022
Q3 		$238M Buy
3,852,296
+3,563,851
+1,236% +$249M 0.26% 80
2022
Q2 		$23M Sell
288,445
-287,728
-50% -$27.2M 0.01% 663
2022
Q1 		$60.6M Buy
576,173
+419,265
+267% +$40.9M 0.05% 366
2021
Q4 		$16.9M Sell
156,908
-35,363
-18% -$3.86M 0.01% 1015
2021
Q3 		$21.1M Sell
192,271
-16,851
-8% -$1.75M 0.01% 860
2021
Q2 		$19.6M Buy
209,122
+41,309
+25% +$3.8M 0.01% 906
2021
Q1 		$15.4M Buy
167,813
+72,095
+75% +$6.08M 0.01% 899
2020
Q4 		$7M Buy
95,718
+91,095
+1,970% +$6.77M ﹤0.01% 1330
2020
Q3 		$359K Sell
4,623
-3,454
-43% -$238K ﹤0.01% 3469
2020
Q2 		$449K Sell
8,077
-1,463
-15% -$62.6K ﹤0.01% 3422
2020
Q1 		$282K Sell
9,540
-17,719
-65% -$599K ﹤0.01% 4039
2019
Q4 		$987K Sell
27,259
-143,389
-84% -$4.4M ﹤0.01% 3688
2019
Q3 		$4.65M Sell
170,648
-236,309
-58% -$6.11M ﹤0.01% 1915
2019
Q2 		$9.79M Buy
406,957
+270,415
+198% +$6.86M 0.01% 1367
2019
Q1 		$3.61M Buy
136,542
+103,800
+317% +$2.46M ﹤0.01% 1955
2018
Q4 		$640K Sell
32,742
-122,012
-79% -$2.39M ﹤0.01% 3580
2018
Q3 		$3.03M Sell
154,754
-25,503
-14% -$485K ﹤0.01% 2398
2018
Q2 		$2.98M Sell
180,257
-36,180
-17% -$552K ﹤0.01% 2180
2018
Q1 		$3.07M Sell
216,437
-147,756
-41% -$2.18M ﹤0.01% 2046
2017
Q4 		$5.32M Sell
364,193
-1,212,788
-77% -$17M ﹤0.01% 1621
2017
Q3 		$20M Buy
1,576,981
+1,415,286
+875% +$18M 0.02% 671
2017
Q2 		$1.92M Sell
161,695
-1,140,446
-88% -$14.2M ﹤0.01% 2285
2017
Q1 		$19.2M Buy
1,302,141
+1,145,968
+734% +$18.6M 0.02% 567
2016
Q4 		$2.53M Sell
156,173
-1,582
-1% -$28.7K ﹤0.01% 1932
2016
Q3 		$2.86M Sell
157,755
-136,493
-46% -$2.67M ﹤0.01% 1710
2016
Q2 		$4.85M Buy
294,248
+151,481
+106% +$2.45M 0.01% 1334
2016
Q1 		$2.28M Sell
142,767
-145,032
-50% -$2.54M ﹤0.01% 1803
2015
Q4 		$6.04M Buy
287,799
+100,133
+53% +$1.95M 0.01% 1189
2015
Q3 		$3.57M Buy
187,666
+66,619
+55% +$2.1M ﹤0.01% 1607
2015
Q2 		$4.12M Buy
121,047
+101,960
+534% +$3.11M ﹤0.01% 1656
2015
Q1 		$478K Buy
19,087
+12,620
+195% +$231K ﹤0.01% 3649
2014
Q4 		$77K Sell
6,467
-25,359
-80% -$317K ﹤0.01% 5398
2014
Q3 		$383K Buy
31,826
+18,771
+144% +$218K ﹤0.01% 4196
2014
Q2 		$196K Sell
13,055
-1,395
-10% -$19.9K ﹤0.01% 4836
2014
Q1 		$217K Buy
14,450
+11,665
+419% +$132K ﹤0.01% 4709
2013
Q4 		$20K Buy
2,785
+1,540
+124% +$8.3K ﹤0.01% 6725
2013
Q3 		$4K Sell
1,245
-468
-27% -$1.23K ﹤0.01% 7063
2013
Q2 		$4K Buy
+1,713
New +$4.11K ﹤0.01% 7428

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's HZNP Position: Q4 2023 in Review

Barclays sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 699,553 shares — an estimated $80.9M sold.

Barclays first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $238M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Barclays reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 699,553 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.9M.
  • Barclays first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Barclays's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $238M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.